SCHEMBL17100764

SCHEMBL17100764

CSc1ccc(S(=O)(=O)N2CCN(c3nc(C(F)(F)c4ccc(F)cc4)no3)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.49
HSD11B1 P28845 3/20 0.47
TSHR P16473 2/20 0.44
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 4/20 0.41
LMNA P02545 4/20 0.41
MEN1 O00255 2/20 0.41
HTT P42858 2/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HPGD P15428 1/20 0.41
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100821 0.91 HSD11B1 (0.46) PKMHSD11B1TSHRKMT2ALMNA
SCHEMBL17100799 0.91 TSHR (0.44) PKMHSD11B1TSHRKMT2AALDH1A1
SCHEMBL17100665 0.90 HSD11B1 (0.49) PKMHSD11B1TSHRKMT2AALDH1A1
SCHEMBL17100667 0.86 HSD11B1 (0.50) PKMHSD11B1TSHRKMT2AALDH1A1
SCHEMBL17100902 0.84 PKM (0.49) PKMHSD11B1TSHRKMT2AALDH1A1
SCHEMBL17100836 0.83 HSD11B1 (0.43) PKMHSD11B1TSHRKMT2AALDH1A1
SCHEMBL17100797 0.78 HSD11B1 (0.49) PKMHSD11B1TSHRKMT2AALDH1A1
SCHEMBL17100778 0.78 PKM (0.46) PKMHSD11B1TSHRKMT2AALDH1A1
SCHEMBL17100720 0.78 TSHR (0.47) PKMHSD11B1TSHRKMT2AALDH1A1
SCHEMBL17100679 0.78 PKM (0.55) PKMHSD11B1TSHRKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US claimed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US claimed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP claimed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT PKM 362/4885HSD11B1 528/4885TSHR 1833/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT PKM 354/4885HSD11B1 648/4885TSHR 1962/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT PKM 362/4885HSD11B1 528/4885TSHR 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.